Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENTHRANE vs ARISTADA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Penthrane (methoxyflurane) is a volatile halogenated ether anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and central nervous system depression. It also sensitizes the myocardium to catecholamines and produces nephrotoxic fluoride ions via metabolism.
Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.
Induction and maintenance of general anesthesia,Analgesia for short-duration procedures (off-label)
Schizophrenia,Maintenance monotherapy of bipolar I disorder in adults
0.2-0.5% inspired concentration via inhalation for analgesia; for general anesthesia, up to 2% inspired via vaporizer.
Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.
Terminal elimination half-life ranges from 1.5 to 4 hours, reflecting slow washout due to high fat solubility and prolonged release from adipose tissue. Clinically, this can lead to prolonged sedation and risk of fluoride-induced nephrotoxicity.
Terminal elimination half-life of aripiprazole lauroxil (the prodrug in ARISTADA) is approximately 54 days (range 29-74 days) after IM injection, allowing monthly dosing.
Primarily hepatic via cytochrome P450 enzymes (CYP2E1), releasing inorganic fluoride ions; approximately 50% is metabolized.
Aripiprazole lauroxil is hydrolyzed by esterases to N-hydroxymethyl aripiprazole, which is then converted to aripiprazole. Aripiprazole is primarily metabolized by CYP2D6 and CYP3A4.
Approximately 50% of absorbed methoxyflurane is eliminated unchanged by the lungs; the remainder is metabolized, primarily via hepatic CYP450 isoenzymes, with fluoride ion and other metabolites excreted renally. Biliary/fecal elimination is negligible (<1%).
Primarily renally excreted (approximately 60% as metabolites, <1% unchanged). Fecal elimination accounts for about 20%.
40–50% bound to plasma proteins, primarily albumin.
>99% bound, primarily to albumin.
Vd approx 2.0–3.5 L/kg, reflecting extensive distribution into adipose tissue and slow equilibration.
Approximately 4.9 L/kg (based on aripiprazole), indicating extensive tissue distribution.
Inhalation: 100% via pulmonary route (no first-pass metabolism). Not administered orally or parenterally in clinical use.
Intramuscular: 100% (complete release from injection site). Oral aripiprazole: 87%.
No specific GFR-based dose adjustments; use with caution in severe renal impairment due to potential nephrotoxicity from fluoride ions.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to potential hepatotoxicity.
No dosage adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of studies.
Not recommended for children due to risk of nephrotoxicity and hepatotoxicity; alternative agents preferred.
Safety and efficacy not established in pediatric patients under 18 years of age.
Use lower inspired concentrations (e.g., 0.2-0.5%) and monitor closely for hypotension and respiratory depression; consider reduced dose due to decreased renal and hepatic function.
No specific dosage adjustment recommended, but caution due to potential increased sensitivity and renal function decline. Monitor for adverse effects and consider lower initial doses if clinically appropriate.
Not approved for use in the United States; has been associated with fatal hepatotoxicity and nephrotoxicity, particularly when used at high doses or for prolonged periods.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.
Hepatotoxicity and nephrotoxicity due to fluoride ion accumulation; myocardial sensitization to catecholamines; malignant hyperthermia risk; respiratory depression; dose-dependent renal impairment.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events in elderly patients with dementia,Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Orthostatic hypotension,Leukopenia, neutropenia, and agranulocytosis,Seizures,Body temperature dysregulation,Dysphagia,Potential for cognitive and motor impairment
Hypersensitivity to halogenated anesthetics; known or suspected susceptibility to malignant hyperthermia; significant hepatic or renal impairment; concurrent use of nephrotoxic agents.
Hypersensitivity to aripiprazole or any component of the formulation
No direct food interactions are documented. However, methoxyflurane metabolism may be affected by hepatic enzyme inducers or inhibitors. Avoid excessive consumption of grapefruit juice as it may inhibit CYP2E1, potentially altering drug metabolism. Maintain adequate hydration to help reduce the risk of nephrotoxicity.
Avoid grapefruit juice due to CYP3A4 inhibition. No specific food restrictions beyond that.
First trimester: Limited human data; animal studies show fetal toxicity at high doses. Potential risk of congenital anomalies cannot be excluded. Second and third trimesters: May cause fetal hypotension and bradycardia; avoid prolonged or high-dose exposure. Near term: Risk of neonatal respiratory depression.
Aristada (aripiprazole lauroxil) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, aripiprazole caused developmental toxicity, including teratogenic effects, at doses similar to or less than the maximum recommended human dose (MRHD). During the first trimester, there is a potential risk of major congenital malformations, although data are limited. During the second and third trimesters, exposure may increase the risk of extrapyramidal symptoms and/or withdrawal symptoms in neonates, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder.
Unknown if excreted in human milk. M/P ratio not established. Caution advised; consider benefits of breastfeeding vs. potential risk to infant.
Aripiprazole is excreted in human breast milk; the milk-to-plasma ratio (M/P) is approximately 0.5 to 3.0 based on limited data. In lactating women, the relative infant dose (RID) is estimated to be about 1.4% to 8.3% of the weight-adjusted maternal dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for Aristada and any potential adverse effects on the breastfed child. Monitor the infant for signs of sedation, extrapyramidal symptoms, or inadequate weight gain.
No specific dose adjustments recommended due to limited data. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy; use lowest effective dose for shortest duration.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) may reduce aripiprazole levels. Although no specific dose adjustment guidelines are established for Aristada, therapeutic drug monitoring of aripiprazole and its active metabolite dehydroaripiprazole may be considered to maintain efficacy. Dose adjustments should be individualized based on clinical response and tolerability, with careful monitoring during pregnancy and postpartum.
Penthrane (methoxyflurane) is a volatile inhalational anesthetic with potent analgesic properties at subanesthetic doses. It is primarily used for emergency pain relief via a handheld inhaler (Penthrox). Key clinical pearls: (1) Nephrotoxicity is dose-dependent due to inorganic fluoride metabolites; limit exposure to a maximum of 6 m L over a week. (2) Avoid concurrent use of tetracyclines or aminoglycosides due to increased nephrotoxic risk. (3) Caution in patients with renal impairment, hepatic disease, or malignant hyperthermia susceptibility. (4) Rapid onset of analgesia within 2-5 breaths; monitor for excessive sedation or respiratory depression. (5) Do not use in patients with cardiovascular instability or hypovolemia as it can cause myocardial depression.
Initiate with a single 672 mg test dose to confirm tolerability. Administer only via gluteal IM injection; do not administer IV. The drug forms a liquid crystal depot upon injection. Ensure proper needle selection: 2-inch needle for gluteal injection. Do not massage injection site. Monitor for post-injection syndrome (rare but serious).
Penthrane is used to relieve moderate to severe pain from trauma or procedures.,Inhale from the device as instructed; do not swallow the liquid.,You may feel drowsy or dizzy; avoid driving or operating machinery for at least 24 hours after use.,Do not consume alcohol or take other central nervous system depressants without consulting your doctor.,Report any signs of kidney injury such as decreased urination, swelling, or fatigue.,Use only as directed and do not exceed the prescribed dose or duration.,Keep the inhaler out of reach of children and do not share with others.
Do not stop taking this medication abruptly; continue regular visits for injections.,Report any severe muscle stiffness, fever, confusion, or irregular heartbeat immediately.,Avoid alcohol and grapefruit juice while on this medication.,You may experience injection site reactions; notify your doctor if they worsen.,Use effective contraception if of childbearing potential; discuss risks with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENTHRANE vs ARISTADA, answered by our medical review team.
PENTHRANE is a Inhaled Anesthetic that works by Penthrane (methoxyflurane) is a volatile halogenated ether anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and central nervous system depression. It also sensitizes the myocardium to catecholamines and produces nephrotoxic fluoride ions via metabolism.. ARISTADA is a Atypical Antipsychotic that works by Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENTHRANE and ARISTADA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENTHRANE is: 0.2-0.5% inspired concentration via inhalation for analgesia; for general anesthesia, up to 2% inspired via vaporizer.. The standard adult dose of ARISTADA is: Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENTHRANE and ARISTADA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENTHRANE is classified as Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Potential risk of congenital anomalies cannot be excluded. Second and third trimesters: May c. ARISTADA is classified as Category C. Aristada (aripiprazole lauroxil) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, aripipr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.